Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/132324
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Eldi, P. | - |
dc.contributor.author | Cooper, T. | - |
dc.contributor.author | Liu, L. | - |
dc.contributor.author | Prow, N. | - |
dc.contributor.author | Diener, K. | - |
dc.contributor.author | Howley, P. | - |
dc.contributor.author | Suhrbier, A. | - |
dc.contributor.author | Hayball, J. | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Molecular Therapy, 2017; 25(10):2332-2344 | - |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.issn | 1525-0024 | - |
dc.identifier.uri | https://hdl.handle.net/2440/132324 | - |
dc.description.abstract | Vaccinia-based systems have been extensively explored for the development of recombinant vaccines. Herein we describe an innovative vaccinia virus (VACV)-derived vaccine platform technology termed Sementis Copenhagen Vector (SCV), which was rendered multiplication-defective by targeted deletion of the essential viral assembly gene D13L. A SCV cell substrate line was developed for SCV vaccine production by engineering CHO cells to express D13 and the VACV host-range factor CP77, because CHO cells are routinely used for manufacture of biologics. To illustrate the utility of the platform technology, a SCV vaccine against chikungunya virus (SCV-CHIK) was developed and shown to be multiplication-defective in a range of human cell lines and in immunocompromised mice. A single vaccination of mice with SCV-CHIK induced antibody responses specific for chikungunya virus (CHIKV) that were similar to those raised following vaccination with a replication-competent VACV-CHIK and able to neutralize CHIKV. Vaccination also provided protection against CHIKV challenge, preventing both viremia and arthritis. Moreover, SCV retained capacity as an effective mouse smallpox vaccine. In summary, SCV represents a new and safe vaccine platform technology that can be manufactured in modified CHO cells, with pre-clinical evaluation illustrating utility for CHIKV vaccine design and construction. | - |
dc.description.statementofresponsibility | Preethi Eldi, Tamara H. Cooper, Liang Liu, Natalie A. Prow, Kerrilyn R. Diener, Paul M. Howley, Andreas Suhrbier, and John D. Hayball | - |
dc.language.iso | en | - |
dc.publisher | Elsevier; American Society of Gene and Cell Therapy | - |
dc.rights | © 2017 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | - |
dc.source.uri | http://dx.doi.org/10.1016/j.ymthe.2017.06.017 | - |
dc.subject | Vaccine; chikungunya; vaccinia virus; live vectored vaccines; poxvirus; antibody; vaccine platform | - |
dc.subject.mesh | CHO Cells | - |
dc.subject.mesh | Animals | - |
dc.subject.mesh | Cricetulus | - |
dc.subject.mesh | Vaccinia virus | - |
dc.subject.mesh | Chikungunya virus | - |
dc.subject.mesh | Viral Vaccines | - |
dc.subject.mesh | Antibodies, Viral | - |
dc.subject.mesh | Antibodies, Neutralizing | - |
dc.subject.mesh | Chikungunya Fever | - |
dc.title | Production of a chikungunya vaccine using a CHO cell and attenuated viral-based platform technology | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/j.ymthe.2017.06.017 | - |
dc.relation.grant | http://purl.org/au-research/grants/arc/LP160100633 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1012386 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Diener, K. [0000-0001-8417-5542] | - |
dc.identifier.orcid | Hayball, J. [0000-0002-3089-4506] | - |
Appears in Collections: | Microbiology and Immunology publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_132324.pdf | Published version | 1.83 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.